January 11, 2018
Correction: A previous version of this story mistated the projected timeline for the combined product. It is Q1 this year, not Q1 next year.
WellDoc and Voluntis, two companies with FDA-cleared, clinically validated platforms aimed at the management of Type 2 diabetes, have signed a commercial agreement to combine their technologies and offer joint products in the future.
“My thought is that a...